Nisa Investment Advisors LLC Sells 9,121 Shares of Biogen Inc. $BIIB

Nisa Investment Advisors LLC decreased its position in shares of Biogen Inc. (NASDAQ:BIIB) by 19.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,435 shares of the biotechnology company’s stock after selling 9,121 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Biogen were worth $6,764,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Elevation Point Wealth Partners LLC bought a new position in Biogen in the 2nd quarter valued at about $25,000. Accredited Wealth Management LLC lifted its holdings in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 185 shares during the period. WFA of San Diego LLC acquired a new stake in shares of Biogen during the 2nd quarter worth approximately $32,000. True Wealth Design LLC boosted its position in shares of Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares in the last quarter. Finally, GoalVest Advisory LLC bought a new position in Biogen in the fourth quarter valued at approximately $35,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have commented on BIIB shares. Royal Bank Of Canada boosted their price objective on shares of Biogen from $217.00 to $233.00 and gave the company an “outperform” rating in a research report on Monday, February 9th. UBS Group started coverage on Biogen in a report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price target for the company. Wells Fargo & Company upped their price objective on Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. Citigroup raised their price objective on Biogen from $185.00 to $215.00 and gave the company a “neutral” rating in a research note on Monday, February 9th. Finally, Wolfe Research set a $231.00 target price on Biogen in a research report on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $208.31.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Acquisition adds approved immunology drugs and revenue: Biogen agreed to acquire Apellis for $5.6B, bringing Syfovre and Empaveli into Biogen’s portfolio and accelerating its push into immunology and rare disease — a clear strategic fit that should boost near-term revenue and pipeline depth. Article Title
• Positive Sentiment: Analysts lift targets and maintain conviction: Multiple firms raised price targets and ratings (Oppenheimer to $275/outperform; Canaccord to $245/buy; HC Wainwright to $237/buy), signaling institutional support for the M&A rationale and longer‑term upside. Article Title Article Title
• Neutral Sentiment: Apellis shares surged on the deal — APLS jumped dramatically (reflecting takeover premium), which is expected after an agreed cash offer but does not directly change Biogen’s near-term cash obligations. Article Title
• Neutral Sentiment: CFO frames deal as debt-neutral/strategic: Biogen’s CFO said combined cash flows and balance-sheet management free capacity for further deals, positioning the company to pursue more early-stage acquisitions. This is strategic context rather than an immediate earnings boost. Article Title
• Neutral Sentiment: Mixed analyst stance: Wedbush raised its price target modestly to $191 but kept a neutral rating, underscoring some caution among analysts despite other upgrades. Article Title
• Negative Sentiment: Investor selling on cash outlay and short-term dilution/near-term risk: Some market participants sold BIIB after the deal announcement, viewing the $5.6B cash use as a near-term headwind despite strategic merits — this is likely the proximate cause of today’s downside. Article Title
• Negative Sentiment: Legal scrutiny on the sale: A plaintiff firm announced an investigation into the adequacy of the Apellis sale price/process, creating a small but nonzero regulatory/legal overhang that could delay or complicate closing. Article Title

Biogen Stock Down 3.5%

Shares of NASDAQ:BIIB opened at $177.34 on Friday. Biogen Inc. has a 52-week low of $110.04 and a 52-week high of $202.41. The company has a market capitalization of $26.03 billion, a PE ratio of 20.13, a price-to-earnings-growth ratio of 1.46 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The company has a fifty day moving average of $186.48 and a 200-day moving average of $171.11.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the previous year, the company posted $3.44 EPS. Biogen’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities analysts predict that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.18% of the stock is owned by corporate insiders.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.